Webdisclosure.com

Search

SANOFI-AVENTIS (EPA:SAN) FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma

Directive transparence : information réglementée

20/10/2021 23:30